Drug intelligence / Profile preview

MBI-07-01

Development stage: Unknown
Lead developer: Matrix Biomed
Modality: Small Molecules
Administration: Ophthalmic, Topical

Overview

MBI-07-01 (also referred to as MBM-01 ophthalmic solution) is a Tempol-based small molecule therapeutic being developed by Matrix Biomed for ocular diseases. It is designed to target and modulate hypoxia-inducible factor 1 (HIF-1) and hypoxia-inducible factor 2 (HIF-2), which are critical transcriptional regulators of the cellular response to low oxygen levels. These factors play a significant role in the pathogenesis of neovascular and degenerative eye conditions. Formulated as a topical ophthalmic solution, MBI-07-01 is currently in Phase 1 clinical development for the treatment of macular degeneration and glaucoma.

Other names: MBM-01MBM01MBM 01

Targets

HIF-1 (Hypoxia-inducible factor 1)EPAS1 (Hypoxia-inducible factor 2-alpha)

Beyond the preview

Go deeper on MBI-07-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MBI-07-01.

Explore the full profile